These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9808502)

  • 1. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.
    Ocran KW; Plauth M; Mai I; Lochs H
    Z Gastroenterol; 1999 Oct; 37(10):1025-8. PubMed ID: 10549098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
    Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 5. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 7. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 8. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 9. Mibefradil: a new class of calcium-channel antagonists.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 12. Good news for experimental concept but bad news for clinically effective therapy.
    Reimer KA; Califf RM
    Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
    [No Abstract]   [Full Text] [Related]  

  • 13. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
    Massie BM; Lacourcière Y; Viskoper R; Woittiez A; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):27C-33C. PubMed ID: 9286851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
    Pordy R; Woittiez A
    Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
    Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
    Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
    Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.